{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Characterize rate of achievement of full donor chimerism","groups":[{"description":"All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.","id":"OG000","title":"Reduced Intensity Allogeneic Stem Cell Transplantation"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Patients to Achieve Full Donor Chimerism","type":"SECONDARY","unitOfMeasure":"participants"}